Published Technical Disclosure Archive

Advanced Biopolymer Nanoparticle Delivery System

Publication ID: 24-11856948_0010_PTD
Published: October 26, 2025
Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Advanced Biopolymer Nanoparticle Delivery System,” Published Technical Disclosure No. 24-11856948_0010_PTD, Published October 26, 2025, available at https://archive.pr1or.art/24-11856948_0010_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,856,948.

Background and Problem Solved

The original patent disclosed a composite colloidal particle formulation with advanced functionality, but it had limitations in terms of scalability, adaptability, and sensing capabilities. The new invention addresses these limitations by introducing modular, self-organizing biopolymer matrices, fractal-based particle designs, and nanoscale sensor arrays, enabling more efficient and effective biomedical applications.

Novelty and Inventive Step

The new claims introduce a paradigm shift in colloidal particle formulations by incorporating adaptive functionality, self-organizing properties, and sensing capabilities, which are not present in the original patent. The use of modular, fractal-based particle designs, nanoscale sensor arrays, and biohybrid systems represents a significant inventive step, enabling more efficient and effective biomedical applications.

Alternative Embodiments and Variations

Alternative embodiments of the invention could include the use of different biopolymer matrices, particle core materials, or sensor array configurations. Variations of the invention could also include the integration of additional functionalities, such as optical or magnetic properties, or the use of different biological cues for targeted delivery.

Potential Commercial Applications and Market

The present invention has significant commercial potential in the biomedical industry, particularly in the areas of targeted drug delivery, regenerative medicine, and biosensing. The invention could be used to develop more efficient and effective therapeutic agents, diagnostic tools, and medical devices, with potential applications in cancer treatment, tissue engineering, and personalized medicine.

CPC Classifications

SectionClassGroup
A A01 A01N25/22
A A01 A01N25/04
A A01 A01N25/10
A A01 A01N59/20

Field of Art

Colloidal particle engineering, biomaterials, and advanced drug delivery systems, with expertise in biopolymer formulations, nanotechnology, and biomedical applications

Person of Ordinary Skill (PHOSITA) Profile

A skilled practitioner with advanced degrees in chemical engineering, materials science, or bioengineering, possessing extensive knowledge of colloidal systems, polymer chemistry, and nanoscale particle design

Obviousness Rationale

A person having ordinary skill in the art would recognize that the PTD's variations represent predictable extensions of the source patent's core teachings about engineered biodegradable particle formulations. The disclosed modular and adaptive particle systems build directly on the fundamental approach of creating composite colloidal particles with enhanced functionality. The PTD's claims represent logical combinations of known techniques in particle engineering, sensor integration, and biomaterial design that would be apparent to a skilled practitioner.

Obvious Combinations & Variations

Source Patent Element
Engineered biodegradable particle core dispersed in bioadhesive polyelectrolyte solution
PTD Variation
Modular, self-organizing biopolymer matrix with dynamic structural adaptation
Obviousness Reasoning
A PHOSITA would find it obvious to introduce responsive design elements into existing particle systems, as adaptive materials are a known approach in advanced drug delivery technologies
Source Patent Element
Ethanol-based solvent containing dissolved biopolymer
PTD Variation
Bio-inspired, fractal-based particle design mimicking natural biological structures
Obviousness Reasoning
Incorporating biomimetic design principles is a predictable optimization strategy for improving particle performance, utilizing known techniques in biomaterials engineering
Source Patent Element
Composite colloidal particle formulation with advanced functionality
PTD Variation
Integrated nanoscale sensor array for real-time environmental monitoring
Obviousness Reasoning
Adding sensing capabilities to particle systems is a well-established approach in nanotechnology, representing a straightforward extension of existing particle engineering techniques
Source Patent Element
Bioadhesive polyelectrolyte solution for particle dispersion
PTD Variation
Swarm-based colloidal particle system with hierarchical self-assembly
Obviousness Reasoning
Designing particle systems with collective behavior is a predictable innovation in the field, leveraging known principles of emergent system design
Source Patent Element
Biodegradable particle core with potential therapeutic applications
PTD Variation
Genetically engineered, tissue-specific biopolymer matrix for controlled bioactive molecule release
Obviousness Reasoning
Advancing particle core functionality through genetic engineering represents a logical progression in biomedical particle design, utilizing known techniques in molecular biology and materials science
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11856948 and the comprehensive technical variations disclosed herein, a person having ordinary skill in the art would find the claimed innovations obvious and lacking inventive step. The published technical disclosure demonstrates that the claimed particle systems represent predictable combinations of known techniques in colloidal particle engineering, with no evidence of unexpected results or non-obvious technical achievements beyond the scope of ordinary professional capabilities in the field.

Original Patent Information

Patent NumberUS 11,856,948
TitleColloidal particle formulations with advanced functionality
Assignee(s)BENANOVA INC.